Literature DB >> 25427729

Surveillance and diagnostic algorithm for hepatocellular carcinoma proposed by the Liver Cancer Study Group of Japan: 2014 update.

Masatoshi Kudo1, Osamu Matsui, Namiki Izumi, Hiroko Iijima, Masumi Kadoya, Yasuharu Imai.   

Abstract

Surveillance and diagnostic algorithms for hepatocellular carcinoma (HCC) have already been described in guidelines published by the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver and the European Organisation for Research and Treatment of Cancer (EASL-EORTC), and the Japan Society of Hepatology (JSH), but the content of these algorithms differs slightly. The JSH algorithm mainly differs from the other two algorithms in that it is highly sophisticated and considers the functional imaging techniques of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced MRI (EOB-MRI) and Sonazoid contrast-enhanced ultrasound (CEUS) to be very important diagnostic modalities. In contrast, the AASLD and EASL-EORTC algorithms are less advanced and suggest that a diagnosis be made based solely on hemodynamic findings using dynamic CT/MRI and biopsy findings. A consensus meeting regarding the JSH surveillance and diagnostic algorithm was held at the 50th Liver Cancer Study Group of Japan Congress, and a 2014 update of the algorithm was completed. The new algorithm reaffirms the very important role of EOB-MRI and Sonazoid CEUS in the surveillance and diagnosis of liver cancer and is more sophisticated than those currently used in the United States and Europe. This is now an optimized algorithm that can be used to diagnose early-stage to classical HCC easily and highly accurately.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25427729     DOI: 10.1159/000368141

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  39 in total

Review 1.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

Review 2.  2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations.

Authors:  Ashish Kumar; Subrat K Acharya; Shivaram P Singh; Anil Arora; Radha K Dhiman; Rakesh Aggarwal; Anil C Anand; Prashant Bhangui; Yogesh K Chawla; Siddhartha Datta Gupta; Vinod K Dixit; Ajay Duseja; Naveen Kalra; Premashish Kar; Suyash S Kulkarni; Rakesh Kumar; Manoj Kumar; Ram Madhavan; V G Mohan Prasad; Amar Mukund; Aabha Nagral; Dipanjan Panda; Shashi B Paul; Padaki N Rao; Mohamed Rela; Manoj K Sahu; Vivek A Saraswat; Samir R Shah; Praveen Sharma; Sunil Taneja; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2019-09-23

3.  Outcome of hypovascular hepatic nodules with positive uptake of gadoxetic acid in patients with cirrhosis.

Authors:  Katsuhiro Sano; Tomoaki Ichikawa; Utaroh Motosugi; Shintaro Ichikawa; Hiroyuki Morisaka; Nobuyuki Enomoto; Masanori Matsuda; Hideki Fujii
Journal:  Eur Radiol       Date:  2016-06-02       Impact factor: 5.315

4.  Characteristics of Hepatocellular Carcinoma Aggressiveness Factors in Turkish Patients.

Authors:  Hikmet Akkiz; Brian I Carr; Kendal Yalçın K; Vito Guerra; Sedef Kuran; Engin Altıntaş; Oğuz Üsküdar; Ümit Karaoğullarından; Ayşegül Özakyol; Salih Tokmak; Mehmet Yücesoy; Halil İbrahim Bahçeci; Abdulalh Ülkü; Tolga Akçam; Kamil Yalçın Polat; Nazım Ekinci; Halis Şimşek; Necati Örmeci; Abdulalh Sonsuz; Mehmet Demir; Murat Kılıç; Ahmet Uygun; Tuğsan Ballı; Ali Demir; Burcu Arslan; Figen Doran
Journal:  Oncology       Date:  2017-12-06       Impact factor: 2.935

Review 5.  Significant biomarkers for the management of hepatocellular carcinoma.

Authors:  Yasuteru Kondo; Osamu Kimura; Tooru Shimosegawa
Journal:  Clin J Gastroenterol       Date:  2015-04-09

6.  LI-RADS v2014 categorization of hepatocellular carcinoma: Intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI.

Authors:  Ji Soo Song; Eun Jung Choi; Seung Bae Hwang; Hong Pil Hwang; HyeMi Choi
Journal:  Eur Radiol       Date:  2018-06-19       Impact factor: 5.315

Review 7.  Recent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRI.

Authors:  Ijin Joo; Jeong Min Lee
Journal:  Liver Cancer       Date:  2015-12-18       Impact factor: 11.740

8.  Our experience of repeat laparoscopic liver resection in patients with recurrent hepatocellular carcinoma.

Authors:  Hisataka Ogawa; Shin Nakahira; Masashi Inoue; Toshimitsu Irei; Makoto Hasegawa; Kazuya Kato; Keisuke Oyama; Hoshi Himura; Takayuki To; Ryosuke Maki; Hidemi Nishi; Nobuyoshi Ohara; Jota Mikami; Yoichi Makari; Ken Nakata; Masaki Tsujie; Junya Fujita
Journal:  Surg Endosc       Date:  2019-07-18       Impact factor: 4.584

9.  Unenhanced areas revealed by contrast-enhanced abdominal ultrasonography with Sonazoid™ potentially correspond to colorectal cancer.

Authors:  Minoru Tomizawa; Mizuki Togashi; Fuminobu Shinozaki; Rumiko Hasegawa; Yoshinori Shirai; Midori Noritake; Yukie Matsuoka; Hiroaki Kainuma; Yasuji Iwasaki; Kazunori Fugo; Yasufumi Motoyoshi; Takao Sugiyama; Shigenori Yamamoto; Takashi Kishimoto; Naoki Ishige
Journal:  Exp Ther Med       Date:  2016-11-03       Impact factor: 2.447

10.  Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma.

Authors:  Hideaki Takeyama; Toru Beppu; Takaaki Higashi; Takayoshi Kaida; Kota Arima; Katsunobu Taki; Katsunori Imai; Hidetoshi Nitta; Hiromitsu Hayashi; Shigeki Nakagawa; Hirohisa Okabe; Daisuke Hashimoto; Akira Chikamoto; Takatoshi Ishiko; Motohiko Tanaka; Yutaka Sasaki; Hideo Baba
Journal:  Surg Today       Date:  2017-11-07       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.